Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

1. Effectiveness of Motivational Interviewing-Enhanced Behavior Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Community-Based Trial

Effectiveness of Motivational Interviewing-Enhanced Behavior Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Community-Based Trial Effectiveness of Motivational Interviewing-Enhanced Behavior Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Community-Based Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Am Acad Child Adolesc Psychiatry Actions . 2020 Aug 28;S0890-8567(20)31375-7. doi: 10.1016/j.jaac.2020.07.907. Online ahead of print. Effectiveness of Motivational Interviewing-Enhanced Behavior Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Community

2021 EvidenceUpdates

2. Viloxazine (Qelbree) - For the treatment of attention deficit hyperactivity disorder

Viloxazine (Qelbree) - For the treatment of attention deficit hyperactivity disorder Drug Approval Package: QELBREE U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: QELBREE Company: Supernus Pharmaceuticals, Inc. Application Number: 211964 Approval Date: 4/2/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2021 FDA - Drug Approval Package

3. Serdexmethylphenidate and dexmethylphenidate (Azstarys) - For the treatment of Attention Deficit Hyperactivity

Serdexmethylphenidate and dexmethylphenidate (Azstarys) - For the treatment of Attention Deficit Hyperactivity Drug Approval Package: AZSTARYS U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: AZSTARYS Company: Commave Therapeutics SA Application Number: 212994 Approval Date: 3/2/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

4. Systematic Review: Educational Accommodations for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

and adolescents with attention-deficit/hyperactivity disorder (ADHD) often receive instruction and take tests using educational accommodations. This review aims to summarize and integrate the research literature on accommodations for this specific population. Method: Electronic databases in medicine (MEDLINE), psychology (PsycINFO), and education (ERIC) were systematically searched (last update January 13, 2020), with inclusion criteria selecting any document with a focus on accommodations in educational (...) Systematic Review: Educational Accommodations for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Systematic Review: Educational Accommodations for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving

2021 EvidenceUpdates

5. Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up

Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up Collaborators Expand Collaborators Neurofeedback Collaborative Group : , , , , , , , , , , , , , , , , , , , , , , , , , PMID: 32853703 DOI: Item in Clipboard Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up Neurofeedback Collaborative Group . J Am Acad Child Adolesc Psychiatry . 2020 . Show details Display options Display options

2021 EvidenceUpdates

6. Lisdexamfetamine for attention deficit hyperactivity disorder (ADHD)

Lisdexamfetamine for attention deficit hyperactivity disorder (ADHD) Lisdexamfetamine for attention deficit hyperactivity disorder (ADHD) - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Health professionals also need to stay up to date with the latest evidence as it emerges. Our information hub has important information for everyone. Featured topics 17 Feb 2021 22 Feb 2021 24 Dec 2020 22 Dec 2020 (...) Email address* Password* Log in Lisdexamfetamine for attention deficit hyperactivity disorder (ADHD) Adults who are diagnosed retrospectively are now included in PBS listings 9 minutes 16 February 2021 Key points From 1 February 2021, adults retrospectively diagnosed with ADHD after the age of 18 years can be prescribed lisdexamfetamine on the PBS Previously, adults were only eligible if their diagnosis of ADHD had been made between the ages of 6 and 18 years. Before this change, adults diagnosed

2021 National Prescribing Service Limited (Australia)

7. Effect of Parent Training on Health-Related Quality of Life in Preschool Children With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis of Data From a Randomized Controlled Trial

HRQoL in early childhood. PT for ADHD has the potential to improve HRQoL independently of its effects on ADHD symptoms. Clinical trial registration information: A Controlled Study of Parent Training in the Treatment of ADHD in Young Children (D'SNAPP); http://clinicaltrial.gov/; . Keywords: attention-deficit/hyperactivity disorder; health-related quality of life; parent training; preschool children. Copyright © 2020 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All (...) Effect of Parent Training on Health-Related Quality of Life in Preschool Children With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis of Data From a Randomized Controlled Trial Effect of Parent Training on Health-Related Quality of Life in Preschool Children With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis of Data From a Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2021 EvidenceUpdates

9. The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study Full Text available with Trip Pro

The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please (...) choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found that few young people who need ongoing support for their ADHD successfully transfer to adult services, few experience optimal transitional care, and adult ADHD service provision is patchy. {{author}} {{($index , , , , , , , , , , , , , & . Astrid Janssens 1, 2 , Helen Eke 1 , Anna Price

2020 NIHR HTA programme

10. Adult Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder: A Systematic Review of the Literature Full Text available with Trip Pro

. Open access peer-reviewed chapter - ONLINE FIRST Adult Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder: A Systematic Review of the Literature By Anja Plemenitaš Ilješ Submitted: June 29th 2020 Reviewed: August 28th 2020 Published: September 29th 2020 DOI: 10.5772/intechopen.93799 > > ADHD [Working Title] Downloaded: 81 1. Introduction Attention-deficit and hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent symptoms of inattention (...) Adult Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder: A Systematic Review of the Literature Adult Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder: A Systematic Review of the Literature | IntechOpen Submit Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific

2020 ADHD [Working Title]

11. Sensory Processing in Adult ADHD – A Systematic Review Full Text available with Trip Pro

environment is driven by our sensory nervous system and our attentional resources. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, impulsivity, and hyperactivity. While cognitive and behavior dysfunctions have broadly been investigated, sensory processing has received less scientific attention. It has been shown, that children with ADHD show processing and modulatory deficits in multiple sensory domains, but very few studies examine to what (...) sensory nervous system and our attentional resources. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, impulsivity, and hyperactivity. While cognitive and behavior dysfunctions have broadly been investigated, sensory processing has received less scientific attention. It has been shown, that children with ADHD show processing and modulatory deficits in multiple sensory domains, but very few studies examine to what extent these deficits

2020 Research Square

12. Prevalence of comorbidities in children with attention deficit/hyperactivity disorder: Measured and systematic review of care health studies Full Text available with Trip Pro

Prevalence of comorbidities in children with attention deficit/hyperactivity disorder: Measured and systematic review of care health studies Prevalence of comorbidities in children with attention deficit/hyperactivity disorder: Measured and systematic review of care health studies | Revista Mexicana de Neurociencia Toggle navigation Your browser does not support inline frames or is currently configured not to display inline frames. DOI: × Download full article in PDF To download the full

2020 Revista Mexicana de Neurociencia

13. The Effects of Parental Training Interventions on ADHD in Children : A Meta-Analysis Full Text available with Trip Pro

-Analysis 표지보기 SNS 공유 발행기관 대한감각통합치료학회 간행물 대한감각통합치료학회지 KCI 등재 통권 제18권 제1호 (2020.06) 페이지 pp.56-72 저자 , 언어 한국어(KOR) URL https://www.earticle.net/Article/A377406 복사 ※ 기관로그인 시 무료 이용이 가능합니다. 저자의 다른 논문 5,100원 구매하기 인용하기 관심논문등록 원문정보 초록 영어 Objective : The purpose is to analyze the effects of parent training interventions in reducing the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and to provide a basis for the effects. Methods : We collected literature published in international academic journals (...) from 2009 to 2019 through ProQuest and Scopus databases. The search key terms were (ADHD OR Attention Deficit Hyperactivity Disorder) AND (Parent OR Mother OR Father) AND (Training OR Program OR Therapy OR Intervention) AND (Randomized OR Randomised OR Randomly). The PEDro scale was used to evaluate the quality of the studies, and a meta-analysis was conducted through Comprehensive Meta-Analysis 3.0. Results : Of 628 studies that we reviewed, 20 were eligible for inclusion. of parental training

2020 Journal of Korean Society of Sensory Integration Therapists

14. Identifying Potential Moderators of ADHD Summer Treatment Program Outcomes: A Systematic Review Full Text available with Trip Pro

. , Barkley R. A. ( 1997 ). Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD . Psychological Bulletin , 121(1), 65. , Barkley R. A. ( 2006 ). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed.). New York, NY: Guilford Press. Barkley R. A. ( 2013 ). Defiant children: A clinician's manual for assessment and parent training . New York, NY: Guilford Press. Beery S. H. , , Quay H. C. , , & Pelham Jr W. E. ( 2017 (...) , and controls . Journal of Consulting and Clinical Psychology , 83(2), 280. , Hoza B. , , Pelham Jr W. E. , , Sams S. E. , , & Carlson C. ( 1992 ). An examination of the” dosage” effects of both behavior therapy and methylphenidate on the classroom performance of two ADHD children . Behavior Modification , 16(2), 164–192. , Jarrett M. A. , , & Ollendick T. H. ( 2008 ). A conceptual review of the comorbidity of attention-deficit/hyperactivity disorder and anxiety: Implications for future research

2020 The ADHD Report

15. Cannabis use and attention deficit/hyperactivity disorder: a systematic review Full Text available with Trip Pro

syntax included: "cannabis AND ADHD", "Attention-deficit/hyperactivity AND cannabis". Results: 229 related publications were found. Most of the excluded texts corresponded to studies that did not report a causal relationship between cannabis and attention deficit hyperactivity disorder, which was the objective of this systematic review. Those full texts that presented cannabis as a treatment for the disorder or because they reported that people with this diagnosis were more prone to substance use (...) of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry J Ment Sci. 2009;194(3):204-211. [ ] 3. Du Rietz E, Kuja-Halkola R, Brikell I, Jangmo A, Sariaslan A, Lichtenstein P, et al. Predictive validity of parent- and self-rated ADHD symptoms in adolescence on adverse socioeconomic and health outcomes. Eur Child Adolesc Psychiatry. 2017;26(7):857-867. [ ] 4. Cuffe SP, Visser SN, Holbrook JR, Danielson ML, Geryk LL, Wolraich ML, et al. ADHD and Psychiatric Comorbidity: Functional

2020 Anales de la Facultad de Ciencias Médicas (Asunción)

16. Investigating regions of shared genetic variation in attention deficit/hyperactivity disorder and major depressive disorder: A GWAS meta-analysis Full Text available with Trip Pro

Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University , UK Frances Rice 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University , UK Richard J. L. Anney 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University , UK Abstract Attention deficit/hyperactivity disorder (ADHD) demonstrates a high (...) Investigating regions of shared genetic variation in attention deficit/hyperactivity disorder and major depressive disorder: A GWAS meta-analysis Investigating regions of shared genetic variation in attention deficit/hyperactivity disorder and major depressive disorder: A GWAS meta-analysis | bioRxiv Search for this keyword New Results Investigating regions of shared genetic variation in attention deficit/hyperactivity disorder and major depressive disorder: A GWAS meta-analysis Victoria Powell

2020 Cold Spring Harbor Laboratory

17. Attention-deficit hyperactivity disorder. (Abstract)

Attention-deficit hyperactivity disorder. Attention-deficit hyperactivity disorder (ADHD), like other psychiatric disorders, represents an evolving construct that has been refined and developed over the past several decades in response to research into its clinical nature and structure. The clinical presentation and course of the disorder have been extensively characterised. Efficacious medication-based treatments are available and widely used, often alongside complementary psychosocial (...) provide an account of the diagnosis, epidemiology, and treatment of ADHD from the perspective of both the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and the eleventh edition of the International Classification of Diseases. Second, we review the progress in our understanding of the causes and pathophysiology of ADHD on the basis of science over the past decade or so. Finally, using these discoveries, we explore some of the key challenges to both the current models

2020 Lancet

18. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

1 2 ABC: Aberrant Behavior Checklist 3 ASD: autism spectrum disorder 4 ADHD: attention-deficit/hyperactivity disorder 5 AEs: adverse events 6 BR: bedtime resistance 7 CAM: complementary and alternative medicine 8 CBT: cognitive behavioral therapy 9 CSHQ: Children’s Sleep Habit Questionnaire 10 CSHQ-BR: Children’s Sleep Habit Questionnaire-Bed Resistance 11 CSHQ-SOD: Children’s Sleep Habit Questionnaire-Sleep Onset Delay 12 DBC: Developmental Behavior Checklist 13 FDA: Food and Drug (...) decreased awareness of social and environmental clues that help habituate sleep–wake cycles. 22 Abnormalities in GABAergic, glutamatergic, serotonergic, and dopaminergic systems in ASD 23 16 are also possible contributors. Coexisting conditions such as epilepsy, nocturnal 1 gastroesophageal reflux disorder (GERD), anxiety, depression, bipolar disorder, psychosis, and 2 attention-deficit/hyperactivity disorder (ADHD) can further contribute to sleep problems. Core 3 or co-occurring ASD symptoms

2020 American Academy of Neurology

19. Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V

M, Gasior M, Gao J, Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med 2011; 123(2): 169-176. 16. Shire Development. A phase 4, randomized, double-blind, multi-center, placebocontrolled, parallel-group study evaluating the safety and efficacy of SPD489 on executive function (self-regulation) behaviors in adults with attention-deficit/hyperactivity disorder (ADHD) reporting clinically significant impairment of real-world (...) executive function behavior: study SPD489-403; clinical study report [unpublished]. 2010. 17. Shire Development. A phase 4, randomized, double-blind, multi-center, placebo- controlled, parallel-group study evaluating the safety and efficacy of SPD489 on executive function (Self-regulation) behaviors in adults with attention-deficit/hyperactivity disorder (ADHD) reporting clinically significant impairment of real-world executive function behavior: study SPD489-403; clinical study protocol [unpublished

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Guanfacine (Intuniv) for attention deficit hyperactivity disorder Full Text available with Trip Pro

a suboptimal response to stimulants. PBS listing Authority Required (Streamlined) On 1 March 2019, guanfacine (Intuniv) was listed on the PBS as an Authority Required (Streamlined) listing. It was listed as an adjunctive treatment to stimulant medicines in patients with attention deficit hyperactivity disorder (ADHD). , To receive subsidised treatment, patients must have residual moderate to severe symptoms despite receiving a maximum tolerated dose (MTD) of dexamfetamine, methylphenidate (...) submission for guanfacine are summarised below. ADHD-RS-IV: The Attention Deficit Hyperactivity Disorder Rating Scale IV is an investigator-rated questionnaire. It consists of 18 items that measure ADHD symptoms according to DSM-IV criteria. Scores range from 0 (never) to 54 (always). A between-group minimally clinically important difference (MCID) has not been fully established, but a 30% mean total score change (or 5.2–7.7 points) has been suggested in some publications. CGI-S: For the Clinical Global

2019 National Prescribing Service Limited (Australia)